N-(4-(1H-imidazol-1-yl)benzyl)-4-amino-5-oxo-2-(piperidin-1-yl)-8-((tetrahydrofuran-2-yl)methyl)-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide

ID: ALA491458

Chembl Id: CHEMBL491458

PubChem CID: 44583048

Max Phase: Preclinical

Molecular Formula: C28H32N8O3

Molecular Weight: 528.62

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  Nc1nc(N2CCCCC2)nc2c1c(=O)c(C(=O)NCc1ccc(-n3ccnc3)cc1)cn2CC1CCCO1

Standard InChI:  InChI=1S/C28H32N8O3/c29-25-23-24(37)22(27(38)31-15-19-6-8-20(9-7-19)35-13-10-30-18-35)17-36(16-21-5-4-14-39-21)26(23)33-28(32-25)34-11-2-1-3-12-34/h6-10,13,17-18,21H,1-5,11-12,14-16H2,(H,31,38)(H2,29,32,33)

Standard InChI Key:  CBTKEQMMDLNZJB-UHFFFAOYSA-N

Associated Targets(non-human)

Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasma (6361 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Sgpl1 Sphingosine-1-phosphate lyase 1 (3 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 528.62Molecular Weight (Monoisotopic): 528.2597AlogP: 2.66#Rotatable Bonds: 7
Polar Surface Area: 133.19Molecular Species: NEUTRALHBA: 10HBD: 2
#RO5 Violations: 1HBA (Lipinski): 11HBD (Lipinski): 3#RO5 Violations (Lipinski): 2
CX Acidic pKa: CX Basic pKa: 6.06CX LogP: 3.42CX LogD: 3.41
Aromatic Rings: 4Heavy Atoms: 39QED Weighted: 0.37Np Likeness Score: -1.61

References

1. Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ..  (2009)  Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders.,  52  (13): [PMID:19489538] [10.1021/jm900278w]

Source